House Republicans are taking pharma’s side in the debate over Medicare coverage of the Alzheimer’s drug Aduhelm, and they’ve added a new complaint: that CMS’ proposed policy would exclude people with Down Syndrome. A group of 47 Republicans signed a letter against CMS’ draft national coverage determination that would limit coverage of Aduhelm and other monoclonal antibodies under development to patients in clinical trials. Rep. Cathy McMorris Rodgers (WA), the lead Republican on the Energy & Commerce Committee, brought up...